The studies showed that survodutide therapy led to a maximum placebo-corrected body weight loss of 13.8% by week 16, demonstrating its potential for significant weight loss [110]
& Michalsson, K
Incretin-based drugs are now being investigated and in some cases approved for a wide range of conditions, including cardiovascular disease, chronic kidney disease, sleep apnea, fatty liver disease (MASLD), neurodegenerative disorders, and even substance-use disorders
About 1 in 8 Americans uses GLP-1 drugs for diabetes, weight loss and other chronic conditions, including semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound)
Our Full Hands-on Willow Experience Heres what happened at every stage of ordering from Willow, from the intake flow to the moment the vial reached our hands